Real-World safety, patient-reported outcomes, and glycemic metrics with a 7-Day extended infusion set in adults with Type 1 diabetes using automated insulin delivery systems

Résumé fourni par la source

BACKGROUND: Extended-wear infusion sets (E-iS) allowing up to 7 days of catheter use have recently become available. Real-world evidence of contemporary automated insulin delivery (AID) systems using E-iS remains limited. METHOD: A prospective non-randomized single-arm real-world study in adults with type 1 diabetes using the MiniMed-780G AID system who transitioned from conventional 3-day infusion sets to E-iS was conducted. Clinical variables, device settings, adverse events, and patient-reported outcomes were assessed at baseline, 3 and 6 months. RESULTS: 65 participants were included, 58 completed 6 months of follow-up.Mean catheter wear time increased from 3.6 ± 1.1 to 6.1 ± 2.3 days,(p < 0.001), and reservoir change interval increased from 3.5 ± 1.0 to 5.2 ± 2.3 days,(p < 0.001). Glycemic control remained overall stable, although small changes were observed in some CGM metrics (Time in range-TIR: 80.0 ± 7.1% to 78.0 ± 10.0%, p = 0.014) and slight increases in time above range, while hypoglycemia exposure remained unchanged. HbA1c decreased from 6.8 ± 0.5% to 6.4 ± 1.0%, (p = 0.03). Total daily insulin dose did not change, but insulin use related to infusion set management decreased significantly. Pain at cannula insertion improved from 2.1 ± 1.5 to 1.2 ± 1.1,(p < 0.001), and treatment satisfaction increased from 8.2 ± 1.9 to 9.0 ± 1.2,(p = 0.012). No episodes of severe hypoglycemia or diabetic ketoacidosis occurred. Cannula wear duration was strongly correlated with reservoir change interval (r = 0.712, p < 0.001). At 6 months, 92.3% of participants continued using the E-iS, with 48.3% maintaining the full 7-day wear duration. CONCLUSIONS: In real-world use with an AID system, the E-iS significantly prolonged catheter wear duration and reservoir change intervals while remaining safe and well tolerated. It was associated with high satisfaction and stable glycemic outcomes, supporting E-iS as a practical strategy to reduce the burden of infusion set changes in routine clinical practice.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.